Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Michael S Brown is Director at Regeneron Pharmaceuticals. OQRO lists 5 transactions filed with the SEC under this name, the latest on Nov 3, 2026, each linked to the official Form 4.
Director
Disclosures on record
5
Companies involved
1
Regeneron PharmaceuticalsREGN
5 disclosures · Jan 2026 – Nov 2026 · 1 sold
Oct 30, 2026Sold~$1.69Mdisclosed Nov 3
DetailsOfficial recordOct 30, 20261,929disclosed Nov 3
DetailsAs of the latest filing on , Michael S Brown reported holding 1,380 shares of Regeneron Pharmaceuticals (REGN), worth about $1.27M at the last close of $921 (Nov 20, 2026). In the last 12 months, Michael S Brown sold $1.69M in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals REGN | 1,380 | 1,380 direct | $921 | $1.27M | Oct 30, 2026 |
Is this Michael S Brown’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Oct 30, 20261,929disclosed Nov 3
DetailsOfficial recordJan 2, 2026155disclosed Jan 6
DetailsOfficial recordJan 2, 20261,962disclosed Jan 6
DetailsOfficial recordMichael S Brown has no open-market purchase on record since 2006. Sales in 18 of the 21 years since 2006.
Michael S Brown reported 0 open-market purchases and 192 sales since 2006; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $1.69M1×1 trade |
| 2024 | — | $2.74M2×2 trades |
| 2023 | — | $9.43M6×6 trades |
| 2022 | — | $5.04M17×17 trades |
| 2021 | — | $10.7M21×21 trades |
| 2020 | — | $7.41M17×17 trades |
| 2019 | — | $3.07M4×4 trades |
| 2018 | — | $1.36M7×7 trades |
| 2017 | — | $4.91M10×10 trades |
| 2015 | — | $6.19M8×8 trades |
| 2014 | — | $4.05M7×7 trades |
| 2013 | — | $9.74M12×12 trades |
| 2012 | — | $4.28M9×9 trades |
| 2011 | — | $3.41M12×12 trades |
| 2010 | — | $134K4×4 trades |
| 2008 | — | $250K2×2 trades |
| 2007 | — | $325K47×47 trades |
| 2006 | — | $334K6×6 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Oct 30, 2026, Michael S Brown reported holding 1,380 shares of Regeneron Pharmaceuticals (REGN). At the last close of $921 on Nov 20, 2026, that is about $1.27M. This is the stake disclosed in filings, not a net worth.
No public filing gives Michael S Brown's net worth. What SEC Form 4 shows is the stock stake: 1,380 shares of Regeneron Pharmaceuticals (REGN), about $1.27M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Michael S Brown reported 1 open-market sale worth $1.69M, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Michael S Brown has no open-market purchase on record since 2006. Sales in 18 of the 21 years since 2006.
In SEC filings since 2006: no open-market purchase is on record; the latest open-market sale is from 2026.
Regeneron Pharmaceuticals (REGN), from 2006 to 2026: 0 purchases and 192 sales.
Michael S Brown reported 0 open-market purchases and 192 sales here, 2006 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.